The new agreement expands on an earlier Advanced Clinical Research Program between BioSig and the Mayo clinic signed last March.
“We are pleased to strengthen and broaden our relationship with Mayo Clinic and Mayo Ventures to grow our innovation capabilities and deliver superior medical technology,” founder & exec chair Kenneth Londoner said in a prepared statement.
BioSig said it will work with Dr. Samuel Asirvatham and Dr. K. L. Venkatachalam through the partnership, and expects joint patent filings as a product of the deal.
“Our experience working with Drs. Asirvatham and Venkatachalam has been outstanding and has resulted in three peer reviewed publications to-date. Adding innovation and intellectual property to the equation should raise this collaboration to a whole new level, likely resulting in better diagnosis and treatment of complex arrhythmias in many patients,” prez & CEO Greg Cash said in a press release.
In January, BioSig said it will embark in an institutional investor roadshow in the EU as it seeks funding for its proprietary Pure electrophysiology platform.
The company is developing a cardiac signal acquisition and display system which is designed to assist electrophysiologists in making clinical decisions for patients with abnormal heart rates and rhythms, including atrial fibrillation and ventricular tachycardia.